



Contact:
Financial Relations Board
Melanie Nimrodi
312.546.3508 or mnimrodi@frbir.com
At The Company
Bob McNally
404.727.0971 or bmcnally@geovax.com

FOR IMMEDIATE RELEASE

GeoVax Presents Data at AIDS Vaccine 2008 Conference

October 16, 2008 - GeoVax Labs, Inc. (OTC BB: GOVX), an Atlanta based, publicly traded biopharmaceutical company specializing in the prevention and treatment of infectious diseases, presented data on their AIDS vaccine (trial HVTN 065) at the *AIDS Vaccine 2008* conference, on October 15 in Cape Town, South Africa. This conference comes at an exciting time for GeoVax, which is preparing to enter Phase 2 trials for its vaccine.

The presentation, titled “Two HIV DNA Primes Maximize T Cell Responses Induced by the GeoVax DNA/MVA Vaccine Regimen Administered to Healthy Seronegative Adults (HVTN 065),” was given by Dr. Paul A. Goepfert, M.D., Associate Professor, Division of Infectious Diseases, Department of Medicine, University of Alabama. Dr. Goepfert is the HVTN 065 Protocol Team chair. The trial results reveal the GeoVax DNA and MVA vaccines are safe and immunogenic (stimulate anti-HIV/AIDS immune responses) at both low (1/10th) dose and full doses. Other highlights included:

- GeoVax vaccines were well tolerated with no or mild local and systemic reactions in the majority of trial participants.
- 80 percent of both the low and full dose trial participants responded to the vaccine which stimulated anti-HIV T-cell (white blood cell) and antibody responses.
- More volunteers had antibody responses to the full dose than to the 1/10th dose vaccine, whereas response rates for T cells were similar for the 1/10th and full dose.
- Two DNA primes were more effective than one DNA prime or no DNA primes at eliciting T cell responses.
- The 2nd MVA vaccination positively increased CD8 T cell and antibody responses.

“As the entire world tries to find a solution for the HIV/AIDS crisis, GeoVax, a front runner in the search for an effective vaccine, is on the verge of entering Phase 2 trials,” said Bob McNally, CEO and President of GeoVax Labs, Inc. “The AIDS Vaccine 2008 conference is a meeting of the minds and it gives hope to humankind that we are making progress on finding a solution to this worldwide epidemic.”

The Phase 2a trial will be conducted by the U.S. National Institutes of Health (NIH) supported HIV Vaccine Trials Network (HVTN) and will involve 225 healthy volunteers from the United States and South America. The trial will further evaluate the safety and immunogenicity of the GeoVax preventative vaccine (vaccine administered prior to infection with the HIV virus). The larger Phase 2 human trial will broaden the base of safety and immunogenicity data for the full dose of the GeoVax AIDS vaccine.

(more)



GeoVax Data at AIDS Vaccine 2008 – Page 2

Dr. Harriet Robinson, the developer of the vaccine and GeoVax's Vice President of Research and Development, also presented these same results at the *Viral Vector Vaccines 2008* meeting, at the Wellcome Trust Conference Center near Cambridge, UK, on September 28, 2008.

The *AIDS Vaccine 2008* conference is held by the Global HIV Vaccine Enterprise, an alliance of independent organizations around the world dedicated to accelerating the development of a preventive HIV vaccine by:

- **Shared Scientific Plan:** Implementing a strategic plan for HIV vaccine research that spans vaccine discovery, product development and manufacturing, and clinical trials
- **Increased Resources:** Mobilizing significant new funding to achieve the scientific plan
- **Greater Collaboration:** Promoting more efficient, faster ways for researchers to share successes and failures and avoid duplication of efforts.

About GeoVax Labs, Inc.

GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's AIDS vaccine technology is the subject of 20 issued or filed patent applications. GeoVax AIDS vaccines are designed for use in uninfected people to prevent Acquired Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, should the person ever become infected. GeoVax AIDS vaccines also may be effective as therapeutics, treatment of people already infected with AIDS virus.

GeoVax's core AIDS vaccine technologies were developed by Dr. Harriet Robinson, Senior V.P. of Research and Development, through a collaboration of colleagues at Emory University's Vaccine Center, the National Institutes of Health (NIH), The Centers for Disease Control and Prevention (CDC) and GeoVax.

GeoVax AIDS vaccines have moved forward in human clinical trials conducted by the HIV Vaccine Trials Network (HVTN) based in Seattle, Washington. The HVTN, funded through a cooperative agreement with the National Institutes of Health (NIH), is the largest worldwide clinical trials program dedicated to the development and testing of AIDS vaccines. Preclinical work enabling evaluation of GeoVax DNA and MVA vaccines was funded and supported by NIAID, which provided additional support to GeoVax AIDS vaccine development program with a \$15 million IPCAVD grant awarded in late 2007.

###

Safe Harbor Statement: All statements in this news release, not statements of historical fact, are forward-looking statements. These statements are based on expectations and assumptions on the date of this press release and are subject to numerous risks and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements. Risks and uncertainties include, but are not limited to, whether: GeoVax can develop and manufacture these vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, and other factors over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. Certain matters discussed in this news release are forward-looking statements involving certain risks and uncertainties including, without limitation, risks detailed in the Company's Securities and Exchange Commission filings and reports.